Marine sponges have consistently been the richest source of new marine natural products
with unprecedented chemical scaffolds and potent biological activities that have been …

Abstract Background Approximately 10–30% of men with mCRPC will test positive for AR-V7
using one of two analytically and clinically validated circulating tumor cell (CTC)-based …

Previous studies have demonstrated that the chronic administration of valproic acid (VPA)
suppresses angiogenesis in vivo; however, the mechanisms implicated in VPA-induced …

A critical unmet need for advanced prostate cancer (PCa) patients is optimizing systemic
treatments to maximize the benefit for individuals. The response of patients with metastatic …

Background Until 2015, androgen deprivation therapy (ADT) alone was the standard-of-care
for metastatic hormone-sensitive prostate cancer (mHSPC). In 2015, the CHAARTED and …

Expression of the AR splice variant, androgen receptor variant 7 (AR-V7), in prostate cancer
is correlated with poor patient survival and resistance to AR targeted therapies and taxanes …

Simple Summary Prostate cancer is a leading cause of cancer-related death among males.
Many treatments are available to manage the disease, but despite this, ultimately advanced …

Constitutively active AR-V7, one of the major androgen receptor (AR) splice variants lacking
the ligand-binding domain, plays a key role in the development of castration-resistant …

Androgen receptor (AR) signaling is fundamental to prostate cancer (PC) progression, and
hence, androgen deprivation therapy (ADT) remains a mainstay of treatment. However …

Abstract Lessons Learned In abiraterone‐and/or enzalutamide‐refractory metastatic
castration‐resistant prostate cancer (mCRPC) patients, selinexor led to prostate‐specific …